Search

Your search keyword '"Bernardini, Annalisa"' showing total 18 results
Start Over Author "Bernardini, Annalisa" Publication Year Range Last 50 years
18 results on '"Bernardini, Annalisa"'

1. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Author

Larocca, Alessandra, Bonello, Francesca, Gaidano, Gianluca, D'Agostino, Mattia, Offidani, Massimo, Cascavilla, Nicola, Capra, Andrea, Benevolo, Giulia, Tosi, Patrizia, Galli, Monica, Marasca, Roberto, Giuliani, Nicola, Bernardini, Annalisa, Antonioli, Elisabetta, Rota-Scalabrini, Delia, Cellini, Claudia, Pompa, Alessandra, Monaco, Federico, Patriarca, Francesca, Caravita di Toritto, Tommaso, Corradini, Paolo, Tacchetti, Paola, Boccadoro, Mario, and Bringhen, Sara

Published
2021
Full Text
View/download PDF

2. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

Author

Bringhen, Sara, Offidani, Massimo, Palmieri, Salvatore, Pisani, Francesco, Rizzi, Rita, Spada, Stefano, Evangelista, Andrea, Di Renzo, Nicola, Musto, Pellegrino, Marcatti, Magda, Vallone, Roberto, Storti, Sergio, Bernardini, Annalisa, Centurioni, Riccardo, Aitini, Enrico, Palmas, Angelo, Annibali, Ombretta, Angelucci, Emanuele, Ferrando, Paola, Baraldi, Anna, Rocco, Stefano, Andriani, Alessandro, Siniscalchi, Agostina, De Stefano, Valerio, Meneghini, Vittorio, Palumbo, Antonio, Grammatico, Sara, Boccadoro, Mario, and Larocca, Alessandra

Published
2018
Full Text
View/download PDF

3. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Author

Magarotto, Valeria, Bringhen, Sara, Offidani, Massimo, Benevolo, Giulia, Patriarca, Francesca, Mina, Roberto, Falcone, Antonietta Pia, De Paoli, Lorenzo, Pietrantuono, Giuseppe, Gentili, Silvia, Musolino, Caterina, Giuliani, Nicola, Bernardini, Annalisa, Conticello, Concetta, Pulini, Stefano, Ciccone, Giovannino, Maisnar, Vladimír, Ruggeri, Marina, Zambello, Renato, Guglielmelli, Tommasina, Ledda, Antonio, Liberati, Anna Marina, Montefusco, Vittorio, Hajek, Roman, Boccadoro, Mario, and Palumbo, Antonio

Published
2016
Full Text
View/download PDF

4. Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial

Author

Mina, Roberto, primary, Larocca, Alessandra, additional, Corradini, Paolo, additional, Cascavilla, Nicola, additional, Liberati, Anna Marina, additional, Pescosta, Norbert, additional, Fazio, Francesca, additional, Ciccone, Giovannino, additional, Capra, Andrea, additional, Patriarca, Francesca, additional, Bernardini, Annalisa, additional, Rota Scalabrini, Delia, additional, Cea, Michele, additional, Zambello, Renato, additional, Baraldi, Anna, additional, Belotti, Angelo, additional, Boccadoro, Mario, additional, and Bringhen, Sara, additional

Published
2020
Full Text
View/download PDF

5. Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

Author

Zaccaria, Gian Maria, primary, Capra, Andrea, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Montefusco, Vittorio, additional, Di Raimondo, Francesco, additional, Bernardini, Annalisa, additional, Liberati, Anna Marina, additional, Omedé, Paola, additional, Mannina, Donato, additional, Caravita di Toritto, Tommaso, additional, Muccio, Vittorio Emanuele, additional, Cascavilla, Nicola, additional, Montani, Stefania, additional, Patriarca, Francesca, additional, Benevolo, Giulia, additional, Saraci, Elona, additional, Belotti, Angelo, additional, Gaidano, Gianluca, additional, Specchia, Giorgina, additional, Nagler, Arnon, additional, Hajek, Roman, additional, Spencer, Andrew, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Gay, Francesca, additional

Published
2019
Full Text
View/download PDF

6. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Author

Larocca, Alessandra, primary, Mina, Roberto, additional, Offidani, Massimo, additional, Liberati, Anna Marina, additional, Ledda, Antonio, additional, Patriarca, Francesca, additional, Evangelista, Andrea, additional, Spada, Stefano, additional, Benevolo, Giulia, additional, Oddolo, Daniela, additional, Innao, Vanessa, additional, Cangiolosi, Clotilde, additional, Bernardini, Annalisa, additional, Musto, Pellegrino, additional, Amico, Valeria, additional, Fraticelli, Vincenzo, additional, Paris, Laura, additional, Giuliani, Nicola, additional, Falcone, Antonietta Pia, additional, Zambello, Renato, additional, De Paoli, Lorenzo, additional, Romano, Alessandra, additional, Palumbo, Antonio, additional, Montefusco, Vittorio, additional, Hájek, Roman, additional, Boccadoro, Mario, additional, and Bringhen, Sara, additional

Published
2019
Full Text
View/download PDF

7. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

Author

Gambella, Manuela, primary, Omedé, Paola, additional, Spada, Stefano, additional, Muccio, Vittorio Emanuele, additional, Gilestro, Milena, additional, Saraci, Elona, additional, Grammatico, Sara, additional, Larocca, Alessandra, additional, Conticello, Concetta, additional, Bernardini, Annalisa, additional, Gamberi, Barbara, additional, Troia, Rossella, additional, Liberati, Anna Marina, additional, Offidani, Massimo, additional, Rocci, Alberto, additional, Palumbo, Antonio, additional, Cavo, Michele, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Oliva, Stefania, additional

Published
2018
Full Text
View/download PDF

8. Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials

Author

D'Agostino, Mattia, primary, Spencer, Andrew, additional, Musto, Pellegrino, additional, Bringhen, Sara, additional, Angelucci, Emanuele, additional, Ciceri, Fabio, additional, Catalano, Lucio, additional, Salvini, Marco, additional, Baraldi, Anna, additional, Grandi, Sonia, additional, Rambaldi, Alessandro, additional, Bosi, Alberto, additional, Vincelli, Iolanda Donatella, additional, Omedè, Paola, additional, Grasso, Mariella, additional, Marasca, Roberto, additional, Cantonetti, Maria, additional, Bernardini, Annalisa, additional, Cascavilla, Nicola, additional, Patriarca, Francesca, additional, Troia, Rossella, additional, Ria, Roberto, additional, Liberati, Anna Marina, additional, Larocca, Alessandra, additional, di Toritto, Tommaso Caravita, additional, Hajek, Roman, additional, Palumbo, Antonio, additional, Boccadoro, Mario, additional, and Gay, Francesca, additional

Published
2017
Full Text
View/download PDF

9. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

Author

Gambella, Manuela, Omedé, Paola, Spada, Stefano, Muccio, Vittorio Emanuele, Gilestro, Milena, Saraci, Elona, Grammatico, Sara, Larocca, Alessandra, Conticello, Concetta, Bernardini, Annalisa, Gamberi, Barbara, Troia, Rossella, Liberati, Anna Marina, Offidani, Massimo, Rocci, Alberto, Palumbo, Antonio, Cavo, Michele, Sonneveld, Pieter, Boccadoro, Mario, and Oliva, Stefania

Subjects
POLYMERASE chain reaction, REVERSE transcriptase polymerase chain reaction, FLOW cytometry, OLIGONUCLEOTIDE synthesis, ONCOLOGY, MULTIPLE myeloma, PROGRESSION-free survival
Abstract

Background: Minimal residual disease (MRD) is one of the most relevant prognostic factors in patients with multiple myeloma (MM); however, the impact of maintenance therapy on MRD levels remains unclear. Among patients with newly diagnosed MM (NDMM) who received lenalidomide maintenance until they developed disease progression, the role of MRD status as a predictor of progression-free survival (PFS) was evaluated by multiparameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) analysis.Methods: Seventy-three patients with NDMM enrolled in the RV-MM-EMN-441 (clinical trials.gov identifier, NCT01091831) and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial) phase 3 trials who achieved at least a very good partial response after intensification/consolidation were included. The median patient age was 57 years (interquartile range, 53-61 years), and all patients received lenalidomide maintenance until they developed progression. MRD was evaluated on bone marrow after intensification/consolidation, after 6 courses of maintenance, and every 6 months thereafter until clinical relapse using both ASO-RQ-PCR (sensitivity, 10-5 ) and MFC (sensitivity, from 10-4 to 10-5 ).Results: After intensification/consolidation, 33 of 72 patients (46%) achieved a molecular complete response (m-CR), and 44 of 70 (63%) achieved a flow complete response (flow-CR). Almost 27% of patients who were MRD-positive after consolidation became MRD-negative during maintenance. After a median follow-up of 38 months, PFS was prolonged in patients who achieved negative MRD status during maintenance according to results from both ASO-RQ-PCR analysis (hazard ratio, 0.29; 95% confidence interval, 0.14-0.62; P = .0013) and MFC (hazard ratio, 0.19; 95% confidence interval, 0.09-0.41; P < .001). The impact of negative MRD status on PFS was similar in all subgroups (ASCT and no-ASCT; International Staging System stages I, II, and III; high-risk and standard-risk cytogenetics), and the two techniques were highly correlated.Conclusions: MRD status is a stronger predictor of PFS than standard risk factors, and lenalidomide maintenance further increases the rate of negative MRD results. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

10. Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase Ill Trial

Author

Gay, Francesca, Magarotto, Valeria, Petrucci, Maria Teresa, Di Raimondo, Francesco, Pour, Ludek, Caravita, Tommaso, Scudla, Vlastimil, Cafro, Anna Maria, Liberati, Anna Marina, Spada, Stefano, Vladimir, Maisnar, Pescosta, Norbert, Ria, Roberto, Offidani, Massimo, Bringhen, Sara, Bernardini, Annalisa, Patriarca, Francesca, Corradini, Paolo, Foa, Roberto, Cascavilla, Nicola, Catalano, Lucio, Spencer, Andrew, Roman Hajek, Boccadoro, Mario, and Palumbo, Antonio

Published
2015

11. Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials

Author

Gay, Francesca, primary, D'Agostino, Mattia, additional, Hajek, Roman, additional, Bringhen, Sara, additional, Conticello, Concetta, additional, Gaidano, Gianluca, additional, Montefusco, Vittorio, additional, Pezzatti, Sara, additional, Salvini, Marco, additional, Caravita, Tommaso, additional, Cafro, Anna Maria, additional, Cavo, Michele, additional, Ruggeri, Marina, additional, Morabito, Fortunato, additional, Mina, Roberto, additional, Baldini, Luca, additional, Benevolo, Giulia, additional, Guglielmelli, Tommasina, additional, Bernardini, Annalisa, additional, Foà, Roberto, additional, Patriarca, Francesca, additional, Offidani, Massimo, additional, Ria, Roberto, additional, Yehuda, Dina Ben, additional, Petrucci, Maria Teresa, additional, Spencer, Andrew, additional, Palumbo, Antonio, additional, and Boccadoro, Mario, additional

Published
2016
Full Text
View/download PDF

12. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Gilestro, Milena, additional, Muccio, Vittorio Emanuele, additional, Gay, Francesca, additional, Drandi, Daniela, additional, Ferrero, Simone, additional, Passera, Roberto, additional, Pautasso, Chiara, additional, Bernardini, Annalisa, additional, Genuardi, Mariella, additional, Patriarca, Francesca, additional, Saraci, Elona, additional, Petrucci, Maria Teresa, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Caravita, Tommaso, additional, Conticello, Concetta, additional, Rocci, Alberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Palumbo, Antonio, additional, and Omedè, Paola, additional

Published
2016
Full Text
View/download PDF

14. Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial

Author

Gay, Francesca, primary, Magarotto, Valeria, additional, Petrucci, Maria Teresa, additional, Di Raimondo, Francesco, additional, Pour, Luděk, additional, Caravita, Tommaso, additional, Scudla, Vlastimil, additional, Cafro, Anna Maria, additional, Liberati, Anna Marina, additional, Spada, Stefano, additional, Vladimir, Maisnar, additional, Pescosta, Norbert, additional, Ria, Roberto, additional, Offidani, Massimo, additional, Bringhen, Sara, additional, Bernardini, Annalisa, additional, Patriarca, Francesca, additional, Corradini, Paolo, additional, Foà, Roberto, additional, Cascavilla, Nicola, additional, Catalano, Lucio, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2015
Full Text
View/download PDF

15. New pharmacotherapy options for multiple myeloma

Author

Mina, Roberto, Cerrato, Chiara, Bernardini, Annalisa, Aghemo, Elena, and Palumbo, Antonio

Abstract

ABSTRACTIntroduction: Novel agents and the availability of autologous stem-cell transplantation have revolutionized the treatment of patients with multiple myeloma. First-generation novel agents namely thalidomide, lenalidomide, and bortezomib have significantly improved response and survival of patients. Second-generation novel agents such as pomalidomide, carfilzomib, and monoclonal antibodies are being tested both in the newly diagnosed and relapse settings, and results are promising.Areas covered: In this review article, the main results derived from Phase III trials with thalidomide, lenalidomide, and bortezomib for the treatment of myeloma patients, both at diagnosis and at relapse, are summarized. Data about second-generation novel agents such as pomalidomide and carfilzomib are also reported. Newer effective drugs currently under investigation and the promising results with monoclonal antibodies are described.Expert opinion: The availability of new effective drugs has considerably increased the treatment options for myeloma patients. A sequential approach including induction, transplantation (when possible), consolidation, and maintenance is an optimal strategy to achieve disease control and prolong survival. Despite these improvements, the best combination, the optimal sequence, and the proper target of newer drugs need to be defined.

Published
2016
Full Text
View/download PDF

16. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

Author

Manuela Gambella, Barbara Gamberi, Pieter Sonneveld, Elona Saraci, Massimo Offidani, Antonio Palumbo, Alberto Rocci, Annalisa Bernardini, Vittorio Emanuele Muccio, Sara Grammatico, Mario Boccadoro, Stefano Spada, Paola Omedè, Rossella Troia, Concetta Conticello, Michele Cavo, Alessandra Larocca, Milena Gilestro, Anna Marina Liberati, Stefania Oliva, Gambella, Manuela, Omedé, Paola, Spada, Stefano, Muccio, Vittorio Emanuele, Gilestro, Milena, Saraci, Elona, Grammatico, Sara, Larocca, Alessandra, Conticello, Concetta, Bernardini, Annalisa, Gamberi, Barbara, Troia, Rossella, Liberati, Anna Marina, Offidani, Massimo, Rocci, Alberto, Palumbo, Antonio, Cavo, Michele, Sonneveld, Pieter, Boccadoro, Mario, Oliva, Stefania, and Hematology

Subjects
Oncology, Male, medicine.medical_specialty, Cancer Research, Neoplasm, Residual, allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR), maintenance, minimal residual disease (MRD), multiparameter flow cytometry (MFC), multiple myeloma (MM), new diagnosis, Real-Time Polymerase Chain Reaction, Disease-Free Survival, Maintenance Chemotherapy, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Interquartile range, Risk Factors, Internal medicine, hemic and lymphatic diseases, medicine, Humans, Immunologic Factors, 030212 general & internal medicine, Lenalidomide, Multiple myeloma, Very Good Partial Response, business.industry, Hazard ratio, Middle Aged, medicine.disease, Flow Cytometry, Minimal residual disease, Confidence interval, body regions, Treatment Outcome, Clinical Trials, Phase III as Topic, 030220 oncology & carcinogenesis, Female, business, Multiple Myeloma, medicine.drug
Abstract

Background: Minimal residual disease (MRD) is one of the most relevant prognostic factors in patients with multiple myeloma (MM); however, the impact of maintenance therapy on MRD levels remains unclear. Among patients with newly diagnosed MM (NDMM) who received lenalidomide maintenance until they developed disease progression, the role of MRD status as a predictor of progression-free survival (PFS) was evaluated by multiparameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) analysis. Methods: Seventy-three patients with NDMM enrolled in the RV-MM-EMN-441 (clinical trials.gov identifier, NCT01091831) and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial) phase 3 trials who achieved at least a very good partial response after intensification/consolidation were included. The median patient age was 57 years (interquartile range, 53-61 years), and all patients received lenalidomide maintenance until they developed progression. MRD was evaluated on bone marrow after intensification/consolidation, after 6 courses of maintenance, and every 6 months thereafter until clinical relapse using both ASO-RQ-PCR (sensitivity, 10 −5 ) and MFC (sensitivity, from 10 −4 to 10 −5 ). Results: After intensification/consolidation, 33 of 72 patients (46%) achieved a molecular complete response (m-CR), and 44 of 70 (63%) achieved a flow complete response (flow-CR). Almost 27% of patients who were MRD-positive after consolidation became MRD-negative during maintenance. After a median follow-up of 38 months, PFS was prolonged in patients who achieved negative MRD status during maintenance according to results from both ASO-RQ-PCR analysis (hazard ratio, 0.29; 95% confidence interval, 0.14-0.62; P =.0013) and MFC (hazard ratio, 0.19; 95% confidence interval, 0.09-0.41; P

Published
2019
Full Text
View/download PDF

17. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Author

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangiolosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hájek R, Boccadoro M, and Bringhen S

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Treatment Outcome, Bortezomib therapeutic use, Dexamethasone therapeutic use, Lenalidomide therapeutic use, Melphalan therapeutic use, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy, Prednisone therapeutic use
Abstract

Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment for newly diagnosed MM, particularly in patients with high-risk cytogenetics [del(17p), t(4;14) or t(14;16)]. We pooled together data from patients with newly diagnosed MM treated with VMP or Rd induction followed by lenalidomide maintenance 10 mg (Rd-R) enrolled in the GIMEMA-MM-03-05 and EMN01 trials, to evaluate the efficacy of these treatments in different subgroups of patients, focusing on those with standard- and high-risk cytogenetics. Overall, 474 patients were analyzed (VMP: 257 patients; Rd-R: 217 patients). No differences in progression-free survival (hazard ratio=0.96) and overall survival (hazard ratio=1.08) were observed between standard-risk patients treated with VMP or Rd-R, whereas among the high-risk patients, the probabilities of progression (hazard ratio=0.54) and death (hazard ratio=0.73) were lower in the patients treated with VMP than in those treated with Rd-R. In particular, standard-risk patients >75 years benefited less from VMP than from Rd-R (hazard ratio for progression-free survival=0.96; hazard ratio for overall survival=1.81). In this non-randomized analysis, VMP and Rd-R were equally effective in younger (≤75 years), standard-risk patients, while older ones (>75 years) benefited more from Rd-R. In high-risk patients, VMP improved progression-free survival and overall survival irrespective of age. The source trials are registered at ClinicalTrials.gov (NCT01063179 and NCT01093196)., (Copyright© 2020 Ferrata Storti Foundation.)

Published
2020
Full Text
View/download PDF

18. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Author

Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, and Omedè P

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Consolidation Chemotherapy, Disease Progression, Female, Humans, Lenalidomide, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma genetics, Multiple Myeloma pathology, Neoplasm, Residual, Prospective Studies, Thalidomide administration & dosage, Thalidomide therapeutic use, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Biomarkers, Tumor genetics, Multiple Myeloma therapy, Thalidomide analogs & derivatives, Transplantation, Autologous methods
Abstract

We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, and 7 additional patients during maintenance. A molecular marker was identified in 25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional patients during maintenance. A lower MRD value by MFC was found in ASCT patients compared with CRD patients (p=0.0134). Tumor burden reduction was different in patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months while biochemical relapse by a median of 4 months. MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results